Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan.
Department of Nephrology, Bolan Medical College, Quetta, Pakistan.
BMC Nephrol. 2023 May 1;24(1):118. doi: 10.1186/s12882-023-03167-5.
Patients with chronic kidney diseases (CKD) are susceptible to the toxic drug effects if given unadjusted doses. Although Pakistan harbors a high burden of CKD patients, there is limited information available on the frequency, pattern and factors associated with unadjusted drug doses among CKD patients.
This cross-sectional study conducted at Sandeman Provincial Hospital, Quetta included 303 non-dialysis ambulatory CKD patients (glomerular filtration rate < 60 ml/min/1.73m). The patients' data were collected through a purpose designed data collection form. The appropriateness of doses was checked against the renal drug handbook-2018, Kidney Disease Improving Global Outcomes guidelines, British National Formulary-2022, and manufacturer leaflets. Data were analysed by SPSS 23 and multiple binary logistic regression analysis was used to assess the factors associated with receiving inappropriate high doses. A p-value < 0.05 was considered statistically significant.
The patients received a total of 2265 prescription lines, with a median of eight different drugs per patient (interquartile range: 6-9 drugs). A total of 34.5% (783/2265) drugs required dose adjustment. Of these, doses were not adjusted for 56.1% (440) drugs in 162 (53.4%) patients. The most common pharmacological class of drugs requiring dose adjustment were antibiotics (79.1%), followed by antidiabetics (59.2%), diuretics (57.0%), angiotensin converting enzyme inhibitors (56.9%), beta blockers (56.9%), analgesics (56.0%), angiotensin receptor blockers (55.2%), domperidone (53.9%) and antihyperlipidmics (46.1%). Patient's age of 41-60 (OR = 5.76) and > 60 years (OR = 9.49), hypertension (OR = 2.68), diabetes mellitus (OR = 3.47) and cardiovascular diseases (OR = 2.82) had statistically significant association (p-value < 0.05) with inappropriate high doses.
The high frequency of inappropriate high doses suggests an important quality gap in medication dosing for patients with ND-CKD at the study site. Special attention should be paid to the drugs and patients with identified risk factors for receiving inappropriate high doses.
慢性肾病(CKD)患者如果给予未调整剂量的药物,容易受到药物毒性的影响。尽管巴基斯坦的 CKD 患者负担沉重,但有关 CKD 患者未调整剂量的频率、模式和相关因素的信息有限。
这项横断面研究在俾路支省的桑德曼省医院进行,纳入了 303 名非透析门诊 CKD 患者(肾小球滤过率<60 ml/min/1.73m)。通过专门设计的数据收集表收集患者数据。根据肾脏药物手册-2018、肾脏病改善全球结局指南、英国国家处方集-2022 和制造商说明书,检查剂量的适宜性。使用 SPSS 23 进行数据分析,并使用多变量二进制逻辑回归分析评估与接受不适当高剂量相关的因素。p 值<0.05 被认为具有统计学意义。
患者共接受了 2265 条处方,每位患者的中位数为 8 种不同的药物(四分位间距:6-9 种药物)。总共 34.5%(783/2265)的药物需要调整剂量。其中,162 名(53.4%)患者中有 56.1%(440 种)药物的剂量未调整。需要调整剂量的最常见药物类别是抗生素(79.1%),其次是降糖药(59.2%)、利尿剂(57.0%)、血管紧张素转换酶抑制剂(56.9%)、β受体阻滞剂(56.9%)、镇痛药(56.0%)、血管紧张素受体阻滞剂(55.2%)、多潘立酮(53.9%)和调脂药(46.1%)。患者年龄在 41-60 岁(OR=5.76)和>60 岁(OR=9.49)、高血压(OR=2.68)、糖尿病(OR=3.47)和心血管疾病(OR=2.82)与接受不适当高剂量有统计学显著关联(p 值<0.05)。
未调整的高剂量的高频率表明,在研究地点,非透析慢性肾病患者的药物剂量存在重要的质量差距。应特别注意具有确定的接受不适当高剂量风险因素的药物和患者。